Clopidogrel Pharmacogenomics and Risk of Inadequate Platelet Inhibition: US FDA Recommendations

• Rosamond W , FlegalK, FurieK et al.: Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation117(4) , E25–E146 (2008).
   PubMed Web of Science ®Google Scholar
• King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al.: 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation117(2) , 261–295 (2008).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR , BergerPB, MannJT 3rd et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA288(19) , 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Yusuf S , ZhaoF, MehtaSR, ChrolaviciusS, TognoniG, FoxKK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N. Engl. J. Med.345(7) , 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Patti G , ColonnaG, PasceriV, PepeLL, MontinaroA, Di Sciascio G: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation111(16) , 2099–2106 (2005).
   PubMed Web of Science ®Google Scholar
• Lamb E : Top 200 Prescription Drugs of 2007.Pharmacy Times74(5) , 20–23 (2008).
   Google Scholar
• Angiolillo DJ , Fernandez-OrtizA, BernardoE et al.: Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.J. Am. Coll. Cardiol.49(14) , 1505–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , GuzmanLA, BassTA: Current antiplatelet therapies: benefits and limitations.Am. Heart J.156(Suppl. 2) , S3–S9 (2008).
   PubMed Web of Science ®Google Scholar
• Gladding P , WebsterM, OrmistonJ, OlsenS, WhiteH: Antiplatelet drug nonresponsiveness.Am. Heart J.155(4) , 591–599 (2008).
   PubMed Web of Science ®Google Scholar
• Brandt JT , PayneCD, WiviottSD et al.: A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.Am. Heart J.153(1) , 66, E9–E16 (2007).
   PubMed Web of Science ®Google Scholar
• Matetzky S , ShenkmanB, GuettaV et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.Circulation109(25) , 3171–3175 (2004).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , TrenkD, FrelingerAL et al.: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.Circulation116(25) , 2923–2932 (2007).
   PubMed Web of Science ®Google Scholar
• Plosker GL , Lyseng-WilliamsonKA: Clopidogrel: a review of its use in the prevention of thrombosis.Drugs67(4) , 613–646 (2007).
   PubMed Web of Science ®Google Scholar
• Taubert D , von Beckerath N, Grimberg G et al.: Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther.80(5) , 486–501 (2006).
   PubMed Web of Science ®Google Scholar
• Clarke TA , WaskellLA: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.Drug Metab. Dispos.31(1) , 53–59 (2003).
   PubMed Web of Science ®Google Scholar
• Kurihara A , HagiharaK, KazuiM, OzekiT, FaridNA, IkedaT: In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidative steps involved in the active metabolite formation.Drug Metab. Rev.37(Suppl. 2) , 99 (2005).
   Google Scholar
• Hagihara K , KazuiM, YoshiikeM, HondaK, FaridNA, KuriharaA: Abstract 4020: a possible mechanism of poorer and more variable response to clopidogrel than prasugrel. Presented at: American Heart Association Scientific Sessions. New Orleans, LA, USA, 8–12 November (2008).
   Google Scholar
• Desta Z , ZhaoX, ShinJG, FlockhartDA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism.Clin. Pharmacokinet.41(12) , 913–958 (2002).
   PubMed Web of Science ®Google Scholar
• Xie HG , KimRB, WoodAJ, SteinCM: Molecular basis of ethnic differences in drug disposition and response.Annu. Rev. Pharmacol. Toxicol.41 , 815–850 (2001).
   PubMed Web of Science ®Google Scholar
• de Morais SM , WilkinsonGR, BlaisdellJ, NakamuraK, MeyerUA, GoldsteinJA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.J. Biol. Chem.269(22) , 15419–15422 (1994).
   PubMed Web of Science ®Google Scholar
• de Morais SM , WilkinsonGR, BlaisdellJ, MeyerUA, NakamuraK, GoldsteinJA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.Mol. Pharmacol.46(4) , 594–598 (1994).
   PubMed Web of Science ®Google Scholar
• Sim SC , RisingerC, DahlML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.Clin. Pharmacol. Ther.79(1) , 103–113 (2006).
   PubMed Web of Science ®Google Scholar
• Brandt JT , CloseSL, IturriaSJ et al.: Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.J. Thromb. Haemost.5(12) , 2429–2436 (2007).
   PubMed Web of Science ®Google Scholar
• Kim KA , ParkPW, HongSJ, ParkJY: The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.Clin. Pharmacol. Ther.84(2) , 236–242 (2008).
   PubMed Web of Science ®Google Scholar
• Umemura K , FurutaT, KondoK: The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects.J. Thromb. Haemost.6(8) , 1439–1441 (2008).
   PubMed Web of Science ®Google Scholar
• Mega JL , CloseSL, WiviottSD et al.: Cytochrome p-450 polymorphisms and response to clopidogrel.N. Engl. J. Med.360(4) , 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Gurbel PA , BlidenKP, HiattBL, O‘ConnorCM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.Circulation107(23) , 2908–2913 (2003).
   PubMed Web of Science ®Google Scholar
• Michelson AD : Platelet function testing in cardiovascular diseases.Circulation110(19) , E489–E493 (2004).
   PubMed Web of Science ®Google Scholar
• Michelson AD : Methods for the measurement of platelet function.Am. J. Cardiol.103(Suppl. 3) , A20–A26 (2009).
   PubMed Web of Science ®Google Scholar
• Michelson AD , FrelingerAL 3rd, Furman MI: Current options in platelet function testing. Am. J. Cardiol.98(10A) , N4–N10 (2006).
   PubMed Web of Science ®Google Scholar
• Hulot JS , BuraA, VillardE et al.: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.Blood108(7) , 2244–2247 (2006).
   PubMed Web of Science ®Google Scholar
• Fontana P , SenoufD, MachF: Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness.Thromb. Res.121(4) , 463–468 (2008).
   PubMed Web of Science ®Google Scholar
• Frere C , CuissetT, MorangePE et al.: Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.Am. J. Cardiol.101(8) , 1088–1093 (2008).
   PubMed Web of Science ®Google Scholar
• Geisler T , SchaeffelerE, DipponJ et al.: CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.Pharmacogenomics9(9) , 1251–1259 (2008).
   PubMed Web of Science ®Google Scholar
• Giusti B , GoriAM, MarcucciR et al.: Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.Pharmacogenet. Genomics17(12) , 1057–1064 (2007).
   PubMed Web of Science ®Google Scholar
• Trenk D , HochholzerW, FrommMF et al.: Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.J. Am. Coll. Cardiol.51(20) , 1925–1934 (2008).
   PubMed Web of Science ®Google Scholar
• Geisler T , GrassD, BigalkeB et al.: The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score.J. Thromb. Haemost.6(1) , 54–61 (2008).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR , O‘ConnellJR, BlidenKP et al.: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.JAMA302(8) , 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Hochholzer W , TrenkD, BestehornHP et al.: Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.J. Am. Coll. Cardiol.48(9) , 1742–1750 (2006).
   PubMed Web of Science ®Google Scholar
• Bhatt DL , ScheimanJ, AbrahamNS et al.: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.Circulation118(18) , 1894–1909 (2008).
   PubMed Web of Science ®Google Scholar
• Ho PM , MaddoxTM, WangL et al.: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.JAMA301(9) , 937–944 (2009).
   PubMed Web of Science ®Google Scholar
• Gilard M , ArnaudB, Le Gal G, Abgrall JF, Boschat J: Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J. Thromb. Haemost.4(11) , 2508–2509 (2006).
   PubMed Web of Science ®Google Scholar
• Li XQ , AnderssonTB, AhlstromM, WeidolfL: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.Drug Metab. Dispos.32(8) , 821–827 (2004).
   PubMed Web of Science ®Google Scholar
• Blume H , DonathF, WarnkeA, SchugBS: Pharmacokinetic drug interaction profiles of proton pump inhibitors.Drug Saf.29(9) , 769–784 (2006).
   PubMed Web of Science ®Google Scholar
• Gilard M , ArnaudB, CornilyJC et al.: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.J. Am. Coll. Cardiol.51(3) , 256–260 (2008).
   PubMed Web of Science ®Google Scholar
• Barragan P , BouvierJL, RoquebertPO et al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.Catheter Cardiovasc. Interv.59(3) , 295–302 (2003).
   PubMed Web of Science ®Google Scholar
• O‘Donoghue ML , BraunwaldE, AntmanEM et al.: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.Lancet374(9694) , 989–997 (2009).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM , SpielAO, LangIM, KreinerG, ChristG, JilmaB: Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.Am. Heart J.157(1) , 148.E1–E5 (2009).
   PubMed Web of Science ®Google Scholar
• Small DS , FaridNA, PayneCD et al.: Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.J. Clin. Pharmacol.48(4) , 475–484 (2008).
   PubMed Web of Science ®Google Scholar
• Lau WC , WaskellLA, WatkinsPB et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction.Circulation107(1) , 32–37 (2003).
   PubMed Web of Science ®Google Scholar
• Farid NA , SmallDS, PayneCD et al.: Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.Pharmacotherapy28(12) , 1483–1494 (2008).
   PubMed Web of Science ®Google Scholar
• Mitsios JV , PapathanasiouAI, RodisFI, ElisafM, GoudevenosJA, TselepisAD: Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.Circulation109(11) , 1335–1338 (2004).
   PubMed Web of Science ®Google Scholar
• Saw J , SteinhublSR, BergerPB et al.: Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.Circulation108(8) , 921–924 (2003).
   PubMed Web of Science ®Google Scholar
• Vinholt P , PoulsenTS, KorsholmL et al.: The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.Thromb. Haemost.94(2) , 438–443 (2005).
   PubMed Web of Science ®Google Scholar
• Farid NA , PayneCD, SmallDS et al.: Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.Clin. Pharmacol. Ther.81(5) , 735–741 (2007).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM , LangI, ChristG, JilmaB: Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.J. Am. Coll. Cardiol.52(19) , 1557–1563 (2008).
   PubMed Web of Science ®Google Scholar
• Lau WC , GurbelPA, WatkinsPB et al.: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.Circulation109(2) , 166–171 (2004).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , Fernandez-OrtizA, BernardoE et al.: Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel.Arterioscler. Thromb. Vasc. Biol.26(8) , 1895–1900 (2006).
   PubMed Web of Science ®Google Scholar
• Fontana P , HulotJS, De Moerloose P, Gaussem P: Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J. Thromb. Haemost.5(10) , 2153–2155 (2007).
   PubMed Web of Science ®Google Scholar
• Nakamura T , SakaedaT, HorinouchiM et al.: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects.Clin. Pharmacol. Ther.71(4) , 297–303 (2002).
   PubMed Web of Science ®Google Scholar
• Ishikawa T , TsujiA, InuiK et al.: The genetic polymorphism of drug transporters: functional analysis approaches.Pharmacogenomics5(1) , 67–99 (2004).
   PubMed Web of Science ®Google Scholar
• Tang K , NgoiSM, GweePC et al.: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations.Pharmacogenetics12(6) , 437–450 (2002).
   PubMedGoogle Scholar
• Fontana P , DupontA, GandrilleS et al.: Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.Circulation108(8) , 989–995 (2003).
   PubMed Web of Science ®Google Scholar
• Malek LA , KisielB, SpiewakM et al.: Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.Circ. J.72(7) , 1165–1169 (2008).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , Fernandez-OrtizA, BernardoE et al.: Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.Thromb. Res.116(6) , 491–497 (2005).
   PubMed Web of Science ®Google Scholar
• Cuisset T , FrereC, QuiliciJ et al.: Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.Thromb. Res.120(6) , 893–899 (2007).
   PubMed Web of Science ®Google Scholar
• Collet JP , HulotJS, PenaA et al.: Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.Lancet373(9660) , 309–317 (2009).
   PubMed Web of Science ®Google Scholar
• Giusti B , GoriAM, MarcucciR et al.: Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.Am. J. Cardiol.103(6) , 806–811 (2009).
   PubMed Web of Science ®Google Scholar
• Sibbing D , StegherrJ, LatzW et al.: Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.Eur. Heart J.30(8) , 916–922 (2009).
   PubMed Web of Science ®Google Scholar
• Simon T , VerstuyftC, Mary-KrauseM et al.: Genetic determinants of response to clopidogrel and cardiovascular events.N. Engl. J. Med.360(4) , 363–375 (2009).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , BraunwaldE, McCabeCH et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes.N. Engl. J. Med.357(20) , 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Juurlink DN , GomesT, KoDT et al.: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.CMAJ180(7) , 713–718 (2009).
   PubMed Web of Science ®Google Scholar
• Aubert RE , EpsteinRS, TeagardenJR et al.: Abstract 3998: proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcome study. Presented at: American Heart Association Scientific Sessions. New Orleans, LA, USA, 8–12 November (2008).
   Google Scholar
• Dunn SP , MacaulayTE, BrennanDM et al.: Abstract 3999: baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Presented at: American Heart Association Scientific Sessions. New Orleans, LA, USA, 8–12 November (2008).
   Google Scholar
• Ang L , PalakodetiV, KhalidA et al.: Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel.J. Am. Coll. Cardiol.52(13) , 1052–1059 (2008).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , BernardoE, RamirezC et al.: Insulin therapy is associated with platelet dysfunction in patients with Type 2 diabetes mellitus on dual oral antiplatelet treatment.J. Am. Coll. Cardiol.48(2) , 298–304 (2006).
   PubMed Web of Science ®Google Scholar
• Sibbing D , von Beckerath O, Schomig A, Kastrati A, von Beckerath N: Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am. J. Cardiol.100(2) , 203–205 (2007).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , BraunwaldE, AngiolilloDJ et al.: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – Thrombolysis in Myocardial Infarction 38.Circulation118(16) , 1626–1636 (2008).
   PubMed Web of Science ®Google Scholar
• Moreno PR , FusterV: New aspects in the pathogenesis of diabetic atherothrombosis.J. Am. Coll. Cardiol.44(12) , 2293–2300 (2004).
   PubMed Web of Science ®Google Scholar
• Ferreira IA , MockingAI, FeijgeMA et al.: Platelet inhibition by insulin is absent in Type 2 diabetes mellitus.Arterioscler. Thromb. Vasc. Biol.26(2) , 417–422 (2006).
   PubMed Web of Science ®Google Scholar
• Erlinge D , VarenhorstC, BraunOO et al.: Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.J. Am. Coll. Cardiol.52(24) , 1968–1977 (2008).
   PubMed Web of Science ®Google Scholar
• Muller I , BestaF, SchulzC, MassbergS, SchonigA, GawazM: Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement.Thromb. Haemost.89(5) , 783–787 (2003).
   PubMed Web of Science ®Google Scholar
• Blindt R , StellbrinkK, de Taeye A et al.: The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb. Haemost.98(6) , 1329–1334 (2007).
   PubMed Web of Science ®Google Scholar
• Bonello L , PaganelliF, Arpin-BornetM et al.: Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.J. Thromb. Haemost.5(8) , 1630–1636 (2007).
   PubMed Web of Science ®Google Scholar
• Frere C , CuissetT, QuiliciJ et al.: ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.Thromb. Haemost.98(4) , 838–843 (2007).
   PubMed Web of Science ®Google Scholar
• Malinin A , PokovA, SperglingM et al.: Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.Thromb. Res.119(3) , 277–284 (2007).
   PubMed Web of Science ®Google Scholar
• Patti G , NuscaA, MangiacapraF, GattoL, D‘AmbrosioA, Di Sciascio G: Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J. Am. Coll. Cardiol.52(14) , 1128–1133 (2008).
   PubMed Web of Science ®Google Scholar
• Gurbel PA , BeckerRC, MannKG, SteinhublSR, MichelsonAD: Platelet function monitoring in patients with coronary artery disease.J. Am. Coll. Cardiol.50(19) , 1822–1834 (2007).
   PubMed Web of Science ®Google Scholar
• Kuliczkowski W , WitkowskiA, PolonskiL et al.: Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology.Eur. Heart J.30(4) , 426–435 (2009).
   PubMed Web of Science ®Google Scholar
• Gladding P , WebsterM, ZengI et al.: The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.JACC Cardiovasc. Interv.1(6) , 620–627 (2008).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , ShoemakerSB, DesaiB et al.: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.Circulation115(6) , 708–716 (2007).
   PubMed Web of Science ®Google Scholar
• Mehta SR : On behalf of the CURRENT OASIS-7 investigators: A 2X2 factorial randomized trial of optimal clopidogrel and aspirin dosing in patients with ACS undergoing an early invasive strategy with intent for PCI. Presented at: European Society of Cardiology 2009 Congress. Barcelona, Spain, 20–30 August (2009).
   Google Scholar
• Pena A , ColletJP, HulotJS et al.: Can we override clopidogrel resistance?Circulation119(21) , 2854–2857 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL , CloseSL, WiviottSD et al.: Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.Circulation119(19) , 2553–2560 (2009).
   PubMed Web of Science ®Google Scholar
• Jeong YH , LeeSW, ChoiBR et al.: Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.J. Am. Coll. Cardiol.53(13) , 1101–1109 (2009).
   PubMed Web of Science ®Google Scholar
• Chen KY , RhaSW, LiYJ et al.: Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Circulation119(25) , 3207–3214 (2009).
   PubMed Web of Science ®Google Scholar

▪ Websites

• US FDA: Plavix® (clopidogrel bisulfate) 75 mg tablets: Safety Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER) www.fda.gov/Safety/MedWatch/SafetyInformation/ucm165166.htm (Accessed June2009)
   Google Scholar
• Homepage of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee www.cypalleles.ki.se/ (Accessed June2009)
   Google Scholar